Navigation Links
Exosome Diagnostics Presents Data Demonstrating Clinical Applications of Exosome Technology in Brain Cancer, Prostate Cancer, and Alzheimer's Disease at the International Society for Extracellular Vesicles 2013 Annual Meeting
Date:4/16/2013

NEW YORK, April 16, 2013 /PRNewswire/ -- Exosome Diagnostics, a developer of biofluid-based molecular diagnostic products for use in personalized medicine, today announced data demonstrating exosome technology performance in clinical applications which will be presented at the International Society for Extracellular Vesicles 2013 (ISEV 2013) annual meeting, April 16-20, in Boston. The ISEV meeting is the preeminent international conference in the rapidly growing field of exosome and microvesicle research.

"The ability to deliver full-length, high quality mRNA and microRNA from biofluids is critical to development of new research tools and clinical grade in vitro diagnostic tests not subject to the limitations of tissue biopsy," said Dr. Johan Skog , chief science officer of Exosome Diagnostics. "Our Alzheimer's disease findings are especially pertinent to advancing a molecular diagnostic test capable of detecting CNS disorders years before the onset of clinical symptoms when therapeutic intervention could provide the most benefit."

Dr. Skog will give two oral presentations. The first is entitled "Characterization of Exosome RNA as a Tool for Molecular Diagnostics", and will be given at 9:30 a.m. EDT on April 16 during the Frye Halloran Educational Symposium. The latest data on Exosome Diagnostics' proprietary biofluid RNA capture technology for disease biomarkers in urine, blood and cerebrospinal fluid (CSF) will be presented. The second, to be given at 9:45 a.m. EDT on April 20, is entitled "The Use Of CSF Microvesicle RNA For Diagnosis Of Alzheimer's Disease". This  presentation describes differences in CSF exosome microRNA expression associated with Alzheimer's disease and patients with subjective memory complaints but no evidence of Alzheimer's disease. 

James McCullough , chief executive officer of Exosome, said, "We are committed to enabling the research community with high-performance exosome technology RNA isolation kits beginning in 2014 for biomarker discovery from fresh and frozen biofluids.  In addition, we are continuing to advance multi-center in vitro diagnostic development programs in genitourinary (GU) Oncology and CSN disorders."  

Exosome Diagnostics' proprietary technology provides access to a previously unexplored source of genetic information directly from diseased cell populations.  Cells throughout the body shed exosomes into fluids as a natural package delivery system to other cells.  Exosomes carry key genes (mRNA and miRNA transcript) responsible for commanding disease growth that can be accessed quickly and repeatedly from a biofluid for analysis on PCR or next-generation sequencing instruments.  Exosome technology has the potential to allow doctors, researchers and drug developers to take repeated, accurate genetic "snapshots" of disease for diagnostic and therapeutic use without the need for a surgical tissue biopsy.

Exosome Diagnostics will also be presenting a poster on an additional study:

Abstract #37, 8-5:30pm EDT, Wednesday, April 17th:  Utility of Urinary Exosomes/Microvesicles to Non-Invasively Analyze Gene Expression in Prostate Cancer

L.M. Russo , A.N. Scott , P. Motamedinia, K.L. Bate , N. Sadeghi, G. Salazar, M. Lipsky, J. Lin, G. Hruby, K.K. Badani , D.P Petrylak, J.M McKiernan

About Exosome Diagnostics
Exosome Diagnostics is a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes are packaged and shed into all biofluids, including blood, urine and CSF, providing a stable source for intact, cell-specific nucleic acids. The Company's proprietary exosome technology makes use of the presence and natural stability of RNA in exosomes to detect and measure levels of genes responsible for cancer and other diseases. The Company is commercializing exosome technology products for use in both the life sciences and clinical settings. For more information, please visit www.exosomedx.com.

Exosome Contact:
James McCullough
Chief Executive Officer
Exosome Diagnostics
(646) 843-4949

Exosome Media Contact:
Robert Flamm , Ph.D.
Russo Partners
(212) 845-4226
robert.flamm@russopartnersllc.com


'/>"/>
SOURCE Exosome Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical (AEMD) Note: Cancer Research Discovery - Melanoma Exosomes Fuel Organ Metastasis
2. Aethlon Medical Announces Notice of Allowance of U.S. Patent Application Covering a Medical Device to Remove Microvesicular Particles, Including Exosomes
3. Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Trial Blood Samples at 2013 American Association of Cancer Research Annual Meeting
4. QBC Diagnostics Awarded GSA Contract
5. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
6. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
7. Ariosa Diagnostics to Present and Exhibit at the 16th International Conference on Prenatal Diagnosis and Therapy
8. ZINO Society Targets Medical Devices, Healthcare IT and Diagnostics
9. Quest Diagnostics To Speak At The Wells Fargo Securities 2012 Healthcare Conference
10. Breakthrough Prostate Cancer Diagnostics
11. NicOx Signs Worldwide Licensing Agreement With Rapid Pathogen Screening, Inc. For Ophthalmic Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
Breaking Medicine Technology:
(Date:10/13/2017)... Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD ... dose required and providing a CBD form that can be easily incorporated into liquid ...
(Date:10/13/2017)... ... , ... Lori R. Somekh, founder of the Law Office of Somekh ... law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up ... network with elder law attorneys nationwide,” said Somekh. , ElderCounsel was ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
Breaking Medicine News(10 mins):